|Articles|November 22, 2013
BBK Worldwide Builds on Tablet Function in Latest Version of Study eBinder
Author(s)Lisa Henderson
BBK Worldwide announced the latest version its Study eBinder
Advertisement
BBK Worldwide announced the latest version its Study eBinder, which addresses more customization for its tablet that study teams use. Version 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff in its proprietary patient recruitment portal, TrialCentralNet (TCN®). The new version also is fully customizable for the sponsor's brand and content.
You can read the full release here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement